4D pharma files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
4d Pharma PLC (DDDD.L) Longevity extends Business Combination deadline
Longevity receives shareholder approval to extend business combination deadline
4d Pharma PLC (DDDD.L) Proposed Merger & Intention to seek NASDAQ Listing
Leeds, UK – 22 October 2020, – 4D pharma plc (AIM: DDDD) (“4D” or the “Company”), a pharmaceutical company leading the development of Live Biotherapeutic Products (“LBPs”), and Longevity Acquisition
4d Pharma PLC (DDDD.L) Presentations on MRx0518 at SITC 2020
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
4d Pharma PLC (DDDD.L) Interim Results
Interim results for the six months ended 30 June 2020
4d Pharma PLC (DDDD.L) MRx0158 Keytruda Part A clinical benefit data
4D pharma announces comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
4d Pharma PLC (DDDD.L) Interim analysis of Blautix phase II study data
Leeds, UK, April 17, 2020 – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the key findings of a planned interim analysis